Esophageal Cancer Treatment in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS — CURATIVE INTENT:

• Histologically confirmed esophageal SCC or adenocarcinoma (biopsy via upper GI endoscopy with EUS-guided sampling)

• Clinical staging T1b–T4a, N0–N3, M0 (resectable or borderline resectable disease per AJCC 8th Edition TNM staging)

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0–2

• Adequate cardiopulmonary reserve: FEV1 > 1.5 L (or >60% predicted), DLCO > 60%, LVEF ≥ 50% on echocardiography (ECHO)

• Adequate hepatic and renal function (bilirubin <1.5× ULN, creatinine clearance >60 mL/min)

• Nutritional status permitting: BMI assessment, pre-albumin >15 g/dL, or optimization achievable via enteral support

• REQUIRED DIAGNOSTIC WORKUP BEFORE TRAVEL:

• Upper GI endoscopy with biopsy (histology, HER2 IHC/FISH for adenocarcinoma)

• Endoscopic Ultrasound (EUS) for T and N staging

• PET-CT scan (18F-FDG) — whole body, for M-staging and treatment response assessment

• High-resolution CT chest/abdomen/pelvis with IV contrast

• Pulmonary function tests (PFTs): spirometry and DLCO

• 2D Echocardiogram (LVEF assessment prior to anthracycline or trastuzumab use)

• Complete blood count, comprehensive metabolic panel, CEA, CA 19-9 (tumor markers)

• Laryngoscopy (if SCC with upper-third involvement, to assess vocal cord mobility)

• Nutritional assessment by registered dietitian

• RELATIVE OR ABSOLUTE CONTRAINDICATIONS:

• Distant metastatic disease (M1) — palliative rather than curative protocol applies

• Tracheoesophageal fistula (complex surgical planning required; assess case-by-case)

• Severe COPD (FEV1 <1.0 L) or oxygen-dependent respiratory failure

• Uncontrolled cardiac disease (recent MI within 6 months, uncontrolled arrhythmia, LVEF <40%)

• ECOG Performance Status 3–4 (poor tolerance for surgical or chemoradiation protocols)

• Active autoimmune disease (relative contraindication for immunotherapy agents)

• Cervical esophageal SCC with tracheal/laryngeal invasion (often requires laryngopharyngoesophagectomy — assess at specialized head and neck oncology center)

ENDOSCOPIC RESECTION (Stage T1a/T1b, Early Disease):

• Endoscopic Mucosal Resection (EMR): Suitable for flat, superficial lesions confined to the mucosa (<2 cm). Uses submucosal injection and snare resection. Low morbidity, outpatient or short-stay procedure.

• Endoscopic Submucosal Dissection (ESD): Preferred for larger en bloc resection of T1a lesions. Provides superior R0 resection margins and intact specimen for histopathological assessment. Requires expert endoscopist; available at tertiary centers in Mumbai, Chennai, Delhi, Dubai, and Abu Dhabi.

• Radiofrequency Ablation (RFA): Used for Barrett's esophagus with high-grade dysplasia or residual flat Barrett's post-EMR, to reduce metachronous cancer risk.

SURGICAL RESECTION (Stage T1b–T3, Resectable T4a):

• Ivor Lewis Esophagectomy (transthoracic, two-field): Right thoracotomy + laparotomy with intrathoracic anastomosis. Gold-standard approach for mid-to-lower esophageal and GEJ tumors. Allows two-field lymphadenectomy (mediastinal + abdominal).

• McKeown Esophagectomy (three-stage, three-field): Right thoracotomy + laparotomy + left neck incision with cervical anastomosis. Preferred for upper and mid-esophageal SCC with cervical lymph node involvement. Allows three-field lymphadenectomy.

• Transhiatal Esophagectomy (THE): Laparotomy + left neck incision without thoracotomy. Lower pulmonary morbidity; suitable for high-risk pulmonary patients, but limited mediastinal visualization.

• Minimally Invasive Esophagectomy (MIE — Thoracoscopic + Laparoscopic): Now the preferred approach at high-volume centers. Meta-analyses confirm significantly reduced pulmonary complications, shorter ICU stay, and equivalent oncological outcomes versus open surgery. Requires laparoscopic gastric conduit formation and thoracoscopic esophageal mobilization.

• Robotic-Assisted Minimally Invasive Esophagectomy (RAMIE): Performed with the da Vinci Surgical System (Xi platform). Offers 3D magnification, articulated instrumentation, and tremor filtration — particularly advantageous for precise lymphadenectomy in the paratracheal and subcarinal nodes. Available at AIIMS New Delhi, Tata Memorial Mumbai, Apollo Hospitals, Medanta, Cleveland Clinic Abu Dhabi, and Mediclinic City Hospital Dubai. Studies (TIME trial, ROBOT trial) confirm non-inferior oncological safety and superior short-term surgical outcomes versus open esophagectomy.

• Gastric Conduit Reconstruction: Standard conduit for esophageal replacement. Colonic or jejunal interposition used when stomach is unavailable (e.g., prior gastric surgery).

CHEMORADIOTHERAPY (Neoadjuvant, Definitive, or Adjuvant):

• Neoadjuvant Concurrent Chemoradiotherapy (nCRT) — CROSS Protocol: Carboplatin AUC2 + Paclitaxel 50 mg/m² weekly × 5 weeks, concurrent with 41.4 Gy in 23 fractions. Standard for resectable Stage II–III disease. Achieves pCR in ~29% (SCC) and ~23% (adenocarcinoma).

• FLOT Protocol (Perioperative Chemotherapy for GEJ Adenocarcinoma): 5-FU + Leucovorin + Oxaliplatin + Docetaxel — 4 cycles pre-op and 4 cycles post-op. Superior to ECF/ECX regimens (FLOT4 trial). Preferred for resectable GEJ and lower esophageal adenocarcinoma.

• Definitive Chemoradiotherapy (dCRT): For cervical esophageal SCC or patients unfit for surgery. 50.4 Gy (conventional fractionation) + concurrent cisplatin/5-FU or carboplatin/paclitaxel. Achieves long-term local control in ~25–30% of SCC patients.

• Radiation Technology: Intensity-Modulated Radiation Therapy (IMRT), Volumetric Modulated Arc Therapy (VMAT), and Image-Guided Radiation Therapy (IGRT) are standard at accredited centers, minimizing dose to heart, lungs, and spinal cord. Proton Beam Therapy (PBT) is available at select centers in India (Apollo Proton Cancer Centre, Chennai) for cases with high pulmonary toxicity risk.

TARGETED THERAPY & IMMUNOTHERAPY:

• HER2-Positive Adenocarcinoma: Trastuzumab (Herceptin) + cisplatin/capecitabine or oxaliplatin-based chemotherapy (ToGA protocol). HER2 IHC/FISH testing mandatory prior to initiation.

• Adjuvant Immunotherapy: Nivolumab (Opdivo) — 240 mg IV every 2 weeks or 480 mg every 4 weeks for 1 year — for patients with residual pathological disease (non-pCR) after nCRT + esophagectomy (CheckMate 577 approval). Reduces risk of recurrence by 31% (HR 0.69).

• First-Line Metastatic: Nivolumab + chemotherapy (CheckMate 649 for adenocarcinoma; ATTRACTION-3 data for SCC). Pembrolizumab (KEYNOTE-590) for PD-L1 CPS ≥10 tumors. Ramucirumab (anti-VEGFR2) ± paclitaxel for second-line adenocarcinoma.

• Molecular Profiling: Comprehensive genomic profiling (CGP via Foundation One CDx or local NGS panels) recommended for all metastatic patients to identify actionable mutations (FGFR2, MET amplification, MSI-H, NTRK fusions).

PALLIATIVE & SUPPORTIVE INTERVENTIONS:

• Self-Expanding Metal Stent (SEMS) placement for malignant dysphagia palliation

• Percutaneous Endoscopic Gastrostomy (PEG) or jejunostomy for enteral nutrition

• Palliative radiotherapy for dysphagia, bone metastasis, or superior vena cava syndrome

• Best Supportive Care (BSC) with structured palliative care team integration

PHASE 1 — PRE-TRAVEL & REMOTE CONSULTATION (Weeks 1–2):

• Patient submits medical records (endoscopy report, biopsy histology, CT/PET-CT, PFTs, ECHO, blood work) to GAF Healthcare's medical team.

• GAF coordinates a teleconsultation with the treating oncologist and thoracic surgeon at the selected center within 48–72 hours.

• Tumor board (MDT) review completed remotely; treatment plan (surgical vs. chemoradiotherapy vs. multimodal) communicated to patient.

• Cost estimate, visa invitation letter, and logistics plan issued by GAF Healthcare coordinator.

PHASE 2 — ARRIVAL & STAGING CONFIRMATION (Days 1–4 in country):

• Airport pickup by GAF-assigned coordinator; accommodation arranged near hospital.

• Re-staging workup at destination center (repeat PET-CT if >6 weeks old, EUS if not done, repeat labs, anesthesia pre-assessment, nutritional assessment).

• If neoadjuvant chemoradiotherapy is planned (CROSS or FLOT protocol), patient may need to remain 5–6 weeks in country for neoadjuvant treatment before surgery, OR may return home for neoadjuvant treatment locally and return for resection.

• Surgical consent, anesthesia review, and optimization (glycemic control, pulmonary physiotherapy, nutritional loading) completed.

PHASE 3 — SURGICAL PROCEDURE (Day 5 or Day 1 post-neoadjuvant, Duration: 4–8 hours):

• Minimally Invasive Esophagectomy (MIE) or Robotic-Assisted Esophagectomy (RAMIE) performed under general anesthesia with epidural analgesia.

• Thoracoscopic phase: esophageal mobilization, systematic mediastinal lymphadenectomy (target: ≥15 nodes per NCCN guidelines).

• Laparoscopic phase: gastric conduit fashioning (preserving right gastroepiploic arcade), pyloroplasty or pyloromyotomy, feeding jejunostomy placement.

• Anastomosis: intrathoracic (Ivor Lewis) or cervical (McKeown) — performed with circular stapler or hand-sewn technique based on surgeon preference and anatomy.

• Intraoperative neuromonitoring for recurrent laryngeal nerve (in three-stage procedures).

PHASE 4 — ICU & IMMEDIATE POST-OPERATIVE CARE (Days 1–5 post-surgery):

• Admission to thoracic surgical ICU: ventilatory weaning, hemodynamic monitoring, thoracic epidural analgesia management.

• Chest drain and nasogastric tube in situ. Jejunostomy feeding commenced at 24 hours post-operatively.

• Daily assessment for anastomotic leak (most critical complication: incidence 5–15%), pulmonary complications (pneumonia, ARDS: 15–30%), and chylothorax (thoracic duct injury: 2–4%).

• Early mobilization protocol initiated by Day 2.

PHASE 5 — WARD RECOVERY (Days 6–14 post-surgery):

• Contrast swallow study (Gastrografin) performed Day 5–7 to confirm anastomotic integrity before oral intake.

• Progressive oral refeeding: sips of water → semi-liquid diet → soft diet. Jejunostomy feeding continues in parallel.

• Removal of chest drains, urinary catheter, and nasogastric tube as clinically appropriate.

• Respiratory physiotherapy, incentive spirometry, and ambulation milestones (target: walking 200–400 m by Day 7).

• Speech and language therapy assessment for swallowing safety.

• Nutritional counseling: high-protein, low-volume, frequent meals; postural guidance (remain upright 30–45 minutes post meals; head elevation 30° at night to prevent reflux and aspiration).

PHASE 6 — DISCHARGE & PRE-FLIGHT PERIOD (Days 14–42 post-surgery):

• Hospital discharge typically at Days 12–18 post-surgery if all milestones met.

• Patient remains at GAF-arranged accommodation near hospital for 3–4 weeks post-discharge.

• Follow-up clinic visits at Day 14, Day 21, and Day 42 post-surgery for wound review, drain site check, and nutritional assessment.

• Fit-to-fly clearance issued at 6–8 weeks post-esophagectomy: requires confirmed anastomotic healing, stable oral intake, absence of active leak or empyema, and medical review by surgeon.

• Business class or premium economy recommended for international flights (semi-reclined posture reduces aspiration risk; avoid pressure on abdominal incision sites).

PHASE 7 — POST-DISCHARGE SURVEILLANCE & ADJUVANT THERAPY:

• CT chest/abdomen at 3 months post-surgery.

• If adjuvant nivolumab indicated (CheckMate 577): 12-month course initiated 4–8 weeks post-surgery — can often be administered at patient's home country oncology center with GAF-provided treatment protocol and records.

• Endoscopic surveillance: Upper GI endoscopy at 6 and 12 months post-resection.

• 5-year surveillance protocol: CT every 6 months for 2 years, then annually.